At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Apr 27, 2026 at 17:21 ET
Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enables ~30-fold higher MeCP2 expression vs. ssAAV9 and miniMeCP2 is functionally comparable to full-length MeCP2, supporting its Rett syndrome gene therapy design. Data will be presented at ASGCT Annual Meeting (May 11-15, 2026), with longer-term clinical data from REVEAL Phase 1/2 expected later this quarter.
- scAAV9 enabled ~30-fold higher MeCP2 expression compared to ssAAV9 in neuronal cells
- MiniMeCP2 protein demonstrated functional comparability to full-length MeCP2 across molecular and biochemical assays
- Data support translational potential of TSHA-102's construct design for lumbar IT administration
- Longer-term safety and efficacy data from Part A REVEAL Phase 1/2 expected later this quarter
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access